Compare Neurocrine Biosciences Inc (NBIX) vs ServiceNow Inc (NOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs ServiceNow Inc — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B), while ServiceNow Inc trades at $139.78 (market cap $142.54B). The key difference: ServiceNow Inc is far larger — about 9.8× Neurocrine Biosciences Inc's market cap, and ServiceNow Inc is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and ServiceNow Inc for 54 Days on average.
| NBIX | NOW | |
|---|---|---|
Market Cap | $14.60B | $142.54B |
Volume | 1,075,694 | 8,001,761 |
Sector | Health | Technology |
52-Week High | $185.50 | $189.26 |
52-Week Low | $123.10 | $83.00 |
Typical Hold Time | 23 Days | 54 Days |
Enterprise Value | $14.61B | $146.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
ServiceNow (NOW) trades at $139.75, up 1.29% with bullish technical momentum and strong institutional support. The company demonstrates robust revenue growth from $7.2B in 2022 to $13.3B in 2025, with consistent earnings beats and expanding AI capabilities driving investor optimism. Despite premium valuation metrics (P/E 86.17, P/S 9.75), the stock benefits from positive analyst sentiment with 87% buy ratings and a $146.04 consensus target.
NOW presents a compelling growth story with AI revenue surpassing $1B and projected to triple by 2029. However, elevated valuation multiples and competitive pressures from Atlassian and Palantir warrant caution. The stock's upside depends on sustained AI adoption and margin preservation amid increasing investment requirements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About ServiceNow Inc
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →
